{"filings":[{"id":1651196,"accession_number":"0001753926-26-001173","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2026-07-15T14:38:08+00:00","items":["1.01","1.03","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals files Chapter 11, sells substantially all assets to XRAIY LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Chapter 11 on March 30, 2026 in Western District of Pennsylvania.","Entered Asset Purchase Agreement with XRAIY LLC on May 14, 2026 to sell substantially all assets.","Bankruptcy Court approved sale on June 4, 2026 via Sale Order.","Company warns common stock trading is highly speculative; recovery for shareholders uncertain.","Sale is free and clear of liens, claims, and encumbrances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-15","daily_digest_url":"/daily/2026-07-15","daily_digest_rank":9},{"id":103166,"accession_number":"0001753926-26-000577","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.03","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.","Company intends to pursue a 363 sale process to maximize value for creditors.","Seeks customary first-day relief to continue operations, including payroll and cash management.","Company cautions trading in common stock is highly speculative and may not reflect recovery for holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103165,"accession_number":"0001753926-26-000265","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella board member Lori A. Birder resigns effective February 3, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lori A. Birder resigned from Lipella Pharmaceuticals' Board of Directors, effective immediately on February 3, 2026.","Resignation not due to any disagreement with the company on operations, policies or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119404,"accession_number":"0001753926-25-001636","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Naoki Yoshimura to retire from Lipella board effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Naoki Yoshimura notified Lipella of his intention to retire from the Board of Directors, effective December 31, 2025.","The retirement is not the result of any disagreement with the company regarding operations, policies, or practices.","No replacement for the departing director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119403,"accession_number":"0001753926-25-001602","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella Pharmaceuticals CMO and Board Member Michael Chancellor to retire effective Dec 4, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Chancellor notified intention to retire as Chief Medical Officer and Board member.","Retirement effective December 4, 2025; no disagreement with company cited.","Dr. Chancellor's departure planned and not due to policy or operational disputes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135954,"accession_number":"0001753926-25-001525","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 27 patients completed 4-week treatment; no serious adverse events reported.","76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.","Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.","Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152985,"accession_number":"0001753926-25-001003","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.","Common stock now quoted on OTC Pink Market under symbol LIPO; company remains fully reporting with SEC.","CEO Jonathan Kaufman issued stockholder letter detailing plans to submit initial listing application to another national exchange.","Clinical programs LP-310 (oral lichen planus) and LP-10 (hemorrhagic cystitis) continue unaffected; final LP-310 Phase 2a data expected H2 2025.","Company states delisting was not due to financial instability and maintains sufficient capital for development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152984,"accession_number":"0001753926-25-000984","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.","Non-compliance with Listing Rules 5635(d) and 5640 due to Series C preferred and warrants issued in Dec 2024-Mar 2025 private placements.","Common stock now quoted on OTC Markets under symbol LIPO; company exploring other listing venues.","Company disappointed, states business fundamentals intact; continuing clinical development of LP-10 and LP-310.","Lipella remains an SEC reporting company and will continue filing periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152983,"accession_number":"0001753926-25-000962","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella sets 2025 annual meeting for July 21; record date June 18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 annual meeting scheduled for July 21, 2025; record date for voting is June 18, 2025.","Stockholder proposals for inclusion in proxy must be received by June 18, 2025.","Deadline for director nominations and other business under advance notice bylaw is June 20, 2025.","Meeting date moved more than 30 days from 2024 annual meeting (Sept 10, 2024); change disclosed per Rule 14a-5(f)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152982,"accession_number":"0001753926-25-000856","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).","Issuances to investment bank between Dec 2024 and Mar 2025 involved >20% of outstanding shares at a discount to Minimum Price.","Company must respond to Nasdaq Hearings Panel by May 19, 2025; plans to seek shareholder approval and pause conversions/exercises.","No immediate effect on listing of common stock (NASDAQ: LIPO); trading continues pending Panel decision.","No assurance that Lipella will regain compliance or maintain listing; risk of delisting if not successful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152981,"accession_number":"0001753926-25-000842","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).","OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).","No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.","Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152980,"accession_number":"0001753926-25-000623","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.","Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.","Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.","Nasdaq continued listing is subject to compliance; company states it currently remains in compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152979,"accession_number":"0001753926-25-000604","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.03","3.03","9.01"],"status":"ready","headline":"Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.","Amendment modifies existing Certificate of Designation, potentially altering voting or conversion rights of current holders.","Change in authorized shares may indicate future financing or strategic moves by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152978,"accession_number":"0001753926-25-000585","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement for up to $2,641,881 of common stock at market prices.","H.C. Wainwright receives 3.0% cash commission on gross proceeds.","Proceeds will be used for working capital and general corporate purposes.","Shares offered under existing effective S-3 shelf registration.","No obligation to sell; company may suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171771,"accession_number":"0001753926-25-000467","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.","Warrant offering: up to 60,000 warrants at $0.125 each, each exercisable for 1 Series B share ($100) convertible at $2.16.","Placement agent Spartan receives $15,045 fees, 10,326 Series C preferred shares, and warrants for 4,060 common shares.","Registration rights require filing within 30 days; failure triggers 100,000 common shares or cash penalty monthly.","Proceeds from both offerings intended for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171770,"accession_number":"0001753926-25-000425","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.","Net proceeds of $602,580; Spartan Capital received $123,420 in fees, 84,700 Series C voting preferred shares and warrants for 28,924 common shares.","CEO Jonathan Kaufman granted irrevocable voting power over Spartan's issued shares via proxy.","Proceeds from the offering to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171769,"accession_number":"0001753926-25-000381","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella raises $3.79M in third closing of Series B convertible preferred offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.","Over-allotment partially exercised; $385,500 from over-allotment included in gross proceeds.","Conversion price set at $3.00 or $3.13 per common share, subject to adjustment.","Spartan Capital earned $663,960 in fees, received 441,933 Series C shares and warrants for 125,833 common shares.","Second amendment makes Spartan's cash and stock compensation pro rata on total $7.2M across both offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171768,"accession_number":"0001753926-25-000276","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.","Mirror Offering capacity increased to $7,200,000 (including $1,200,000 over-allotment) with registration statements due within 30 days of closings.","Variable Rate Transaction restrictions reduced to 90 days post-termination or 10 business days after Registration Statement effective date if $6,000,000 of shares sold.","Company restricted from disposing securities for 90 days after third closing if all shares under that closing are not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171767,"accession_number":"0001753926-25-000211","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella reports positive Phase 2a results for LP-310 in oral lichen planus; FDA okays expanded access","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved Expanded Access Program for LP-310 (oral rinse for OLP) on Feb 6, 2025.","Phase 2a topline: statistically significant improvements in pain (NRS), IGA, REU, and OLPSSM at weeks 1, 4, 6.","No product-related SAEs, no dropouts; tacrolimus blood levels undetectable or minimal in all patients.","Trial advancing to 0.5 mg dose cohort; recruitment to conclude first half 2025.","Company plans Phase 2b IND submission and Breakthrough Therapy request in second half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171766,"accession_number":"0001753926-25-000078","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Lipella continued listing with conditions; compliance deadline April 14, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Hearings Panel decision on Jan 10, 2025 granting continued listing subject to interim milestones.","Must file disclosure of equity-increasing transactions and provide fundraising update, income projections by April 14, 2025.","Must demonstrate compliance with minimum stockholders' equity requirement and plan to meet minimum bid price.","Company intends to comply but cautions no assurance; failure could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171765,"accession_number":"0001753926-25-000035","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella raises $368K in second closing of Series B preferred offering; CEO gets voting proxy","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second closing issued 3,680 shares of Series B non-voting convertible preferred at $100/share, convertible into 117,948 common shares at $3.12/share.","Net proceeds of $305,440; use for working capital and general corporate purposes.","Placement agent Spartan received $62,560 in fees, 42,933 Series C voting preferred shares, and a warrant for 11,795 common shares.","Spartan granted CEO Jonathan Kaufman irrevocable voting power over all Series C and warrant shares via proxy agreement.","Total offering remains open up to $6.0 million; first closing on Dec 30 sold 22,295 Series B shares for $2.23M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188765,"accession_number":"0001753926-24-002189","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals closes $2.23M initial tranche of Series B preferred offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of $2.23M on Dec 23, 2024: 22,295 Series B shares sold at $100 each.","Net proceeds ~$1.8M; intended for working capital and general corporate purposes.","Series B convertible into 854,214 common shares at $2.61/share; 4.99% ownership cap.","Spartan Capital received ~$334K fees, 260,108 Series C conversion shares, and 85,421 warrants at $1.00.","Maximum offering size $6.0M (up to $7.2M with over-allotment); offering open until June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188764,"accession_number":"0001753926-24-002162","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella special meeting cancelled due to lack of quorum; no action taken","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Reconvened special meeting on Dec 27, 2024, found no quorum present.","No action was taken on the proposal presented at the Special Meeting.","The company did not disclose the nature of the proposed vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188763,"accession_number":"0001753926-24-002130","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella Pharma special meeting adjourned due to lack of quorum; reconvenes Dec 27","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting on Dec 20, 2024 lacked a quorum; adjourned to Dec 27, 2024 at 2:00 p.m. ET.","Valid proxies submitted before original meeting remain valid for reconvened meeting unless revoked.","No proposals were voted on; meeting was virtual.","Company filed definitive proxy statement on Nov 12, 2024 for the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188762,"accession_number":"0001753926-24-002052","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals enters agreement for up to $6M Series B convertible preferred offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of up to $6,000,000 in Series B non-voting convertible preferred stock; underwritten by Spartan Capital Securities.","Placement agent fee: 10% of gross proceeds in cash plus warrants for 10% of conversion shares at $1.00/share, 5-year term.","Separate consulting agreement with Spartan: $300,000 cash fee and 700,000 shares of Series C Preferred Stock for advisory services.","Series C Preferred Stock is junior to other preferred, pari passu with common, convertible 1:1 with 4.99% beneficial ownership limit.","Investors granted right to purchase additional $6M in a Mirror Offering within six months of registration effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188761,"accession_number":"0001753926-24-002047","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella Pharmaceuticals special meeting adjourned due to lack of quorum; reconvenes Dec 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lipella held special meeting Dec 6, 2024; no quorum present; meeting adjourned.","Reconvened special meeting set for Dec 20, 2024 at 2:00 p.m. ET.","Valid proxies from original meeting continue to apply unless changed or revoked.","Meeting related to proposals in Definitive Proxy Statement filed Nov 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188760,"accession_number":"0001753926-24-001824","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals effects 1-for-8 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective Nov 7, 2024; every 8 shares converted to 1 share.","No fractional shares issued; holders paid cash for fractional interests.","Authorized share count unchanged; options and warrants adjusted proportionally.","Common stock trades split-adjusted on Nasdaq Capital Market starting Nov 8.","New CUSIP number for common stock is 53630L 209."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188759,"accession_number":"0001753926-24-001793","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.","Common stock begins trading split-adjusted on November 8, 2024 under symbol LIPO.","Authorized shares unchanged at 200,000,000; par value remains $0.0001 per share.","Split intended to bring company into compliance with Nasdaq minimum bid price requirement.","Approved by stockholders at Annual Meeting on September 10, 2024; CUSIP changes to 53630L209."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188758,"accession_number":"0001753926-24-001716","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq delisting notice for equity deficiency; hearing set for Dec 12","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lipella of delisting for stockholders' equity of $1.7M, below $2.5M minimum.","Company appealed by Oct 23, 2024; hearing before Nasdaq Hearings Panel set for Dec 12, 2024.","Trading suspension stayed pending hearing; stock continues trading on Nasdaq during appeal.","Bid price non-compliance also outstanding; reverse split approved to address minimum bid requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205232,"accession_number":"0001753926-24-001565","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lipella shareholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected (including CEO Jonathan Kaufman); broker non-votes of 1,703,278.","Reverse stock split authorized (3,881,533 for, 407,381 against); board may implement up to 1:150 within one year.","Ratification of auditor Urish Popeck & Co. for FY2024 ratified with 4,232,289 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205231,"accession_number":"0001753926-24-001473","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq delisting notice; equity $1.7M vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lipella on Aug 21, 2024 of non-compliance with $2.5M minimum stockholders' equity requirement.","Company reported stockholders' equity of $1,703,798 in Q2 10-Q, below the $2.5M threshold.","Company must submit compliance plan by Oct 7, 2024; intends to do so.","If plan accepted, Nasdaq may grant up to 180-day extension from Aug 21, 2024.","Failure to regain compliance could result in delisting of LIPO common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205230,"accession_number":"0001753926-24-001361","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella sets 2024 annual meeting for Sept 10; record date Aug 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting moved to Sept 10, 2024, more than 30 days after last year's Nov 21 meeting.","Record date for voting is Aug 1, 2024.","Shareholder proposals for proxy inclusion due by Aug 8, 2024.","Director nominations and other business notices due by Aug 9, 2024.","Universal proxy rule compliance deadline also Aug 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205229,"accession_number":"0001753926-24-001333","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lipella raises $1.28M in registered direct offering of common stock and pre-funded warrants at $0.62/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total offering of 2,066,000 equity units (399K shares + 1,667K pre-funded warrants) at $0.62 per unit.","Gross proceeds ~$1.28M closed August 1, 2024; net proceeds for working capital and general corporate purposes.","H.C. Wainwright served as exclusive placement agent; receives 7.5% cash fee and 154,950 warrants exercisable at $0.775.","Pre-funded warrants exercisable immediately at $0.001/share with 9.99% beneficial ownership blocker.","Company agreed to 30-day lock-up on equity issuance and 1-year restriction on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222114,"accession_number":"0001753926-24-000805","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated April 17, 2024, notes LIPO common stock closing bid price below $1.00 for 30 consecutive business days.","Company has until October 14, 2024 to regain compliance; bid price must close at $1.00 or more for 10 consecutive business days.","If not compliant by Oct 14, may qualify for additional 180-day grace period if meeting other Nasdaq Capital Market listing standards.","Lipella intends to monitor bid price and evaluate available options to cure deficiency; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222113,"accession_number":"0001753926-24-000721","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Lipella eliminates Series A Preferred Stock designation after all shares converted to common","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Series A Elimination Certificate with Delaware Secretary of State on April 11, 2024.","All previously issued Series A Preferred Stock converted into common stock; no shares outstanding.","No further shares will be issued under the Series A designation.","Certificate became effective immediately upon filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241632,"accession_number":"0001753926-24-000545","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CEO and CMO each purchase $100k of Lipella common stock at $0.6901/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jonathan Kaufman bought 144,906 shares for $100,000 at $0.6901/share on March 12, 2024.","CMO Michael Chancellor bought 144,906 shares for $100,000 at same price and date.","Total insider investment of $200,000; shares subject to six-month restricted period.","Proceeds provide working capital; shares issued directly from company treasury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259080,"accession_number":"0001753926-23-001558","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella believes it meets Nasdaq minimum equity rule after $2M private placement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Private placement closed Oct 25, 2023; gross proceeds $2.0M, net ~$1.7M.","Stockholders' equity as-adjusted: ~$3.9M (Sep 30, 2023) and ~$3.8M (Oct 31, 2023), above $2.5M minimum.","Nasdaq will continue to monitor ongoing compliance; no assurance of future compliance.","Previously disclosed Nasdaq delinquency notice on Nov 21, 2023 for minimum equity rule.","Pre-funded warrants issued at $1.519/unit; exercise $0.001 per share; common warrants $1.40, 3-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259079,"accession_number":"0001753926-23-001555","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq deficiency notice for potential minimum equity violation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 21, 2023, for failure to maintain minimum $2.5M stockholders' equity as of Sep 30, 2023.","No immediate effect on listing of LIPO common stock; continues to trade normally.","Company evaluating measures to regain compliance but cannot assure success.","If not remedied, Nasdaq may delist the stock; compliance deadline not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259078,"accession_number":"0001753926-23-001529","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lipella shareholders elect all 7 directors, approve share plan increase, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven director nominees elected with ~2.22M to ~2.24M votes for each; 184,927 broker non-votes.","Amendment to 2020 Stock Incentive Plan approved (1.57M for, 670k against); authorized shares increased by 1M to 2.4M.","Ratification of Urish Popeck & Co. as independent auditor approved (2.42M for, 175 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259077,"accession_number":"0001753926-23-001389","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lipella raises $2M via private placement of pre-funded warrants and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2M from sale of 1,315,790 pre-funded warrants (exercise $0.001) and 1,315,790 warrants (exercise $1.40) at $1.519/unit.","Warrants immediately exercisable, expire in 3 years; exercise price $1.40 per share.","H.C. Wainwright acted as exclusive placement agent; received 7.5% cash fee, 1% mgmt fee, $50k expense allowance, and 98,684 placement agent warrants.","Company agreed to file resale registration statement within 7 business days, effective within 45-75 calendar days.","Net proceeds intended for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276354,"accession_number":"0001753926-23-001209","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lipella presents Phase 2a results for LP-10 at H.C. Wainwright conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11, 2023.","Provided update on product pipeline and Phase 2a clinical trial results for drug candidate LP-10.","Presentation materials posted on company website at lipella.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276353,"accession_number":"0001753926-23-001017","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Lipella raises CEO and CMO salaries by $50k each","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jonathan Kaufman annual base salary increased by $50,000 to $233,300 effective August 4, 2023.","CMO Michael Chancellor annual base salary increased by $50,000 to $225,000 effective August 4, 2023.","Both amendments executed on August 4, 2023; all other terms of existing employment agreements remain unchanged.","The salary increases are reflected in amendments to employment agreements originally dated July 17, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276352,"accession_number":"0001753926-23-000985","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals signs new lease for 3,275 sq ft office/manufacturing space","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with Bridgeway Development for ~3,275 sq ft at 7800 Susquehanna St, Pittsburgh, PA.","Term runs Aug 1, 2023 to June 30, 2025, co-terminating with existing lease; five-year extension option.","Annual base rent starts at ~$27,600 (year 1) and rises to ~$37,000 by final extension year.","Premises will be used for office, manufacturing and assembly work in addition to current space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294058,"accession_number":"0001753926-23-000846","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella appoints Dr. Lori Birder to Board of Directors, effective June 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Birder appointed to the Board effective June 17, 2023, to serve until next annual meeting of stockholders.","She will serve on the Audit Committee and the Compensation Committee.","No arrangements, understandings, or transactions requiring disclosure under Item 404(a) exist with her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294057,"accession_number":"0001753926-23-000765","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella Pharmaceuticals director David Battleman resigns effective June 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. David Battleman notified the Board on May 30, 2023 of his resignation as director.","Resignation effective June 17, 2023, and not due to any dispute or disagreement with the Company.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294056,"accession_number":"0001753926-23-000678","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lipella Pharma Q1 net loss $1.1M; cash $4.0M; Phase 2a LP-10 positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of ~$1.1M for Q1 2023; cash, equivalents, and marketable securities ~$4.0M as of March 31, 2023.","Phase 2a trial for LP-10 (hemorrhagic cystitis) showed positive safety and efficacy top line results; Type B FDA meeting planned in coming months.","Established Scientific Advisory Board for LP-310 (oral lichen planus) with five experts in oral medicine.","Entered manufacturing collaboration with Cook MyoSite to support LP-10 IND application."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":118048.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294055,"accession_number":"0001753926-23-000382","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lipella completes Phase 2a trial of LP-10 for hemorrhagic cystitis; reports $5.1M cash, IPO completed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.","Year-end cash $5.1M, provides operating runway into 2024.","Appointed Douglas Johnston as CFO in November 2022.","Completed IPO and Nasdaq listing in December 2022.","Created Oral Health Scientific Advisory Board for LP-310; results to be presented at AUA meeting April 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314676,"accession_number":"0001753926-23-000301","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella Pharmaceuticals appoints Daniel Cohen to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Daniel Cohen as director on March 21, 2023, expanding board to seven members.","Cohen will serve until the next annual meeting and then stand for election.","He was assigned to the Board's audit committee.","No arrangements or understandings with any other persons regarding his appointment.","Entered into no transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314674,"accession_number":"0001753926-23-000103","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K/A","filed_at":"2023-02-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Lipella amends 8-K to correct investor presentation; no new business details","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Amendment corrects earlier 8-K that mistakenly included an earlier version of the investor presentation.","Corrected presentation (Exhibit 99.1) includes additional slides not in the original filing.","No financial or operational updates disclosed in this amendment; presentation content not excerpted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314675,"accession_number":"0001753926-23-000046","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 subjects tolerated LP-10 without product-related serious adverse events.","Dose response observed: decreased hematuria, cystoscopic bleeding/ulceration, improved urinary symptoms.","Responder analysis: complete response in 3 subjects, partial in 7, no response in 3 subjects.","LP-10 has Orphan Drug Designation; no FDA-approved treatment exists for hemorrhagic cystitis.","CEO to present results at Biotech Showcase 2023 on January 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":462083.99999999994,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-12T23:59:59+00:00|314675"}